James Condulis
Stock Analyst at Stifel Nicolaus
(3.31)
# 2,482
Out of 4,651 analysts
53
Total ratings
55.6%
Success rate
7.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Condulis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AARD Aardvark Therapeutics | Reiterated: Hold | $6 | $6.54 | -8.26% | 5 | Aug 13, 2026 | |
| EWTX Edgewise Therapeutics | Maintained: Hold | $36 | $44.17 | -18.50% | 6 | Aug 11, 2026 | |
| CYTK Cytokinetics | Reiterated: Buy | $108 | $74.13 | +45.69% | 16 | Aug 7, 2026 | |
| XFOR X4 Pharmaceuticals | Maintained: Buy | $10 | $4.22 | +136.97% | 2 | Aug 7, 2026 | |
| TECX Tectonic Therapeutic | Maintained: Buy | $75 | $34.91 | +114.84% | 3 | Aug 7, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintained: Buy | $136 | $100.64 | +35.14% | 8 | Aug 6, 2026 | |
| NAMS NewAmsterdam Pharma Company | Reiterated: Buy | $50 | $26.98 | +85.32% | 5 | Aug 6, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Reiterated: Buy | $98 → $104 | $86.64 | +20.04% | 2 | Aug 5, 2026 | |
| FULC Fulcrum Therapeutics | Downgraded: Hold | $25 → $3 | $3.74 | -19.79% | 5 | Jun 2, 2026 | |
| AMLX Amylyx Pharmaceuticals | Initiated Coverage: Buy | $21 | $21.63 | -2.91% | 1 | Mar 3, 2026 |
Aardvark Therapeutics
Aug 13, 2026
Reiterated: Hold
Price Target: $6
Current: $6.54
Upside: -8.26%
Edgewise Therapeutics
Aug 11, 2026
Maintained: Hold
Price Target: $36
Current: $44.17
Upside: -18.50%
Cytokinetics
Aug 7, 2026
Reiterated: Buy
Price Target: $108
Current: $74.13
Upside: +45.69%
X4 Pharmaceuticals
Aug 7, 2026
Maintained: Buy
Price Target: $10
Current: $4.22
Upside: +136.97%
Tectonic Therapeutic
Aug 7, 2026
Maintained: Buy
Price Target: $75
Current: $34.91
Upside: +114.84%
Mirum Pharmaceuticals
Aug 6, 2026
Maintained: Buy
Price Target: $136
Current: $100.64
Upside: +35.14%
NewAmsterdam Pharma Company
Aug 6, 2026
Reiterated: Buy
Price Target: $50
Current: $26.98
Upside: +85.32%
Arrowhead Pharmaceuticals
Aug 5, 2026
Reiterated: Buy
Price Target: $98 → $104
Current: $86.64
Upside: +20.04%
Fulcrum Therapeutics
Jun 2, 2026
Downgraded: Hold
Price Target: $25 → $3
Current: $3.74
Upside: -19.79%
Amylyx Pharmaceuticals
Mar 3, 2026
Initiated Coverage: Buy
Price Target: $21
Current: $21.63
Upside: -2.91%